Category Archives: Disease

Proteoforms Are the Next New Wave of Innovation and Biology

CPSA Analytics 2021 Imagine Summit

Brad Ackermann, Eli Lilly and Company

Proteins matter. Proteins matter more than any other molecule.” – Brad Ackermann, Eli Lilly and Company

Brad takes us on a tour of the importance of proteins for the understanding and treatment of disease – 99% of drug targets are proteins. The subtle differences in proteoforms and how they associate are not readily differentiated without the use of reliable platforms utilising liquid chromatography combined with mass spectrometry. Furthermore, in order to more fully understand biology we need to understand proteoforms in tissues, in addition to what is in circulation. Brad made it clear that the needs of the 3P’s (Patient, Physician and Payer) are paramount for the delivery of the healthcare of the future.

Considerations from the Frontline for Infectious Disease – COVID-19 Pandemic

7th Annual Brasilian Symposium on Clinical & Pharmaceutical Solutions through Analysis (CPSA BRASIL 2020)

Program Chair – CPSA Brazil 2020
Carlos Kiffer, MD, Ph.D. from Escola Paulista de Medicina / Universidade Federal de São Paulo

“We’re responsible for ourselves as much as we are responsible for our communities.”

“(What COVID-19 brought us) A chance of observing a large number of patients over a small period of time. You start to see patterns.”

“I wish everyone could take care of each other.”

Diseases are complex, and the COVID-19 pandemic presents with several manifestations.  Working in infectious disease for over 30 years, Carlos has observed 100’s to 1000’s of patients and works with friends and colleagues to identify patterns related to these different manifestations.  They work together to make sense of these patterns through observations of patients in the hospitals, as well as using metabolomics, proteomics, and genetics to measure molecular differences in manifestations.  The global pandemic will bring changes to certain approaches used for understanding infectious disease, and Carlos passionately works with community to bring relevant knowledge to design clinical scoring systems to define the spectrum of COVID-19 manifestations.

Considerations on Top Down Proteomics – Development of Diagnosis Tests for Patient

7th Annual Brasilian Symposium on Clinical & Pharmaceutical Solutions through Analysis (CPSA BRASIL 2020)

Proteomics Session Coordinator – CPSA Brazil 2020
Rafael Melani, Ph.D. from Northwestern University

“The development of new technology… of one specific protein can (lead to a) new diagnostic test.”

A passionate explanation of the love to help develop science and methodologies, even in little steps, to increase understanding of human disease with relevant biological knowledge. Technology continues to improve, and Top Down Proteomics (analysis of intact proteins) has developed into a technique that can be used to identify proteins that are involved with complex diseases, such as Cancer described in this CPSA Everyday. Much like people in society, proteins interact in networks working together, or possibly not working in unison. Understanding the complex protein networks help identify disease pathways that lead towards improved health outcomes for patients – with improved data to build relevant biological knowledge.

Proteomics Session Coordinator – Rafael Melani, PhD

Prof. Gilberto Domont, Emeritus Professor, Universidade Federal do Rio de Janeiro

Luca Fornelli, Ph.D, Assistant Professor of Biology, The University of Oklahoma, OK

Roundtable Contributors
Carlos Kiffer, MD, Ph.D.
Marc Chalom